|Bid||0.00 x 3100|
|Ask||0.00 x 800|
|Day's Range||46.90 - 47.01|
|52 Week Range||31.54 - 47.08|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||86.29|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
WILMINGTON, N.C., October 18, 2021--PPD Announces Third Quarter 2021 Earnings Conference Call
WILMINGTON, N.C., October 06, 2021--PPD is the recipient of the 2021 Eagle Award for its commitment to advancing clinical research professionalism through strong site partnerships.
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it has entered into an agreement with PPD, Inc. (Nasdaq: PPD), a leading global contract research organization (CRO), for PPD to oversee the company's clinical studies investigating the Hemopurifier, Aethlon's therapeutic blood filtration system, for infectious disease indications.